Last reviewed · How we verify
SLV354
At a glance
| Generic name | SLV354 |
|---|---|
| Also known as | ABT-354 |
| Sponsor | Abbott |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia (PHASE1)
- This is a Single Ascending Dose Tolerance Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SLV354 CI brief — competitive landscape report
- SLV354 updates RSS · CI watch RSS
- Abbott portfolio CI